Biotech Stocks: Mylan, King lead drug stocks higher
Market Watch (Free subscription) | 10/09/2008
Drug stocks advanced in early action Thursday, led by Mylan Laboratories and King Pharmaceuticals.
Mylan Laboratories
+Vote!
1Vote!
Drug stocks advance; Mylan climbs on debt rate swap
Market Watch (Free subscription) | 10/09/2008
BOSTON (MarketWatch) -- Drug stocks advanced in early action Thursday, led by Mylan Laboratories . The Amex Pharmaceutical Index rose marginally to 264.52 and the Amex Biotechnology Index jumped 2% to 681.36. Shares of Mylan climbed almost 4% to $8.01. The generic drugmaker said that it has swapped $500 million of its debt from a floating rate to a more favorable fixed rate. Mylan's chief financial...
1Vote!
Mylan Announces Tentative Approval For Venlafaxine Hydrochloride Tablets
Acidity Info (Free subscription) | 07/23/2008
Mylan Laboratories Inc. (NYSE: MYL) announced that the U.S. Food and Drug Administration have granted tentative esteem all for Mylan Pharmaceuticals Inc.'s Abb revia ted New Drug Application for Venlafaxine Hydrochloride Tablets 25 mg (base), 37.5 mg (base), 50 mg (base), 75 mg (base) and 100 mg (base). Ranitidine Syrup, the generic alike of GlaxoSmithKline's Zantac(R) Syrup, will be untaken in the...
2Vote!
Mylan gets federal OK for generic Sonata
The Pittsburgh Business Times (Free subscription) | 06/09/2008
Mylan Laboratories Inc. said Monday that it received final approval from the U.S. Food and Drug Administration to sell a generic version of King Pharmaceuticals' insomnia drug Sonata. (KG) (MYL)
1Vote!
Ortho-McNeil Pharmaceutical, Inc. v. Cobalt Pharmaceuticals Inc. (Fed. Cir. 2008)
Patent Docs (Free subscription) | 04/10/2008
By Donald Zuhn -- Last week, the Federal Circuit issued an opinion in Ortho-McNeil Pharmaceutical, Inc. v. Mylan Laboratories, Inc. In Mylan Laboratories, the Federal Circuit determined that the District Court for the District of New Jersey properly construed claim 1 of U.S. Patent No. 4,513,006, owned by Plaintiff-Appellee Ortho-McNeil...
2Vote!
Ortho-McNeil Pharmaceutical, Inc. v. Mylan Laboratories, Inc. (Fed. Cir. 2008)
Patent Docs (Free subscription) | 04/07/2008
By Donald Zuhn -- Last week, the Federal Circuit determined that the District Court for the District of New Jersey properly construed claim 1 of U.S. Patent No. 4,513,006 to encompass Plaintiff-Appellee Ortho-McNeil Pharmaceutical, Inc.'s epilepsy drug topiramate, and affirmed the District Court's decision to (1) permanently enjoin Defendants-Appellees Mylan...
2Vote!
Court Affirms Topamax Ruling
Law Blog - WSJ.com (Free subscription) | 03/31/2008
A federal court affirmed a ruling that blocks Mylan Laboratories from selling a generic epilepsy drug until Johnson & Johnson's Topamax patent expires in September.
3Vote!
Weekly CEO Buys Highlight: NorthStar Realty Finance Corp., Mylan Laboratories Inc., Helix Energy Solutions Group Inc., General Electric Company, IDT Corp.
GuruFocus Updates (Free subscription) | 03/19/2008
This is the highlight of CEO buys for the past week. Related Companies: NorthStar Realty Finance Corp. (NRF), Mylan Laboratories Inc. (MYL), Helix Energy Solutions Group Inc. (HLX), General Electric Company (GE), IDT Corp. (IDT).
1Vote!
Acquisition drags down Mylan
The Pittsburgh Business Times (Free subscription) | 02/27/2008
Mylan Laboratories Inc. said late Wednesday it posted a fiscal third-quarter loss due to the acquisition of Merck KGaA's generics business. (MYL) (FRX)
- add comment
- send to a friend
- Explore : Business, Merck
1Vote!
Mylan swings to third-quarter loss of $5.04 a share
Market Watch (Free subscription) | 02/27/2008
SAN FRANCISCO (MarketWatch) -- Mylan Laboratories Inc. said late Wednesday it swung to a fiscal third-quarter loss of $1.38 billion, or $5.04 a share, from a profit of $135.4 million, or 63 cents a share, a year ago. Excluding the company's recent acquisition of Matrix Labs, the company would have reported earnings of 11 cents a share for the latest quarter. Revenue rose to $1.15 billion from $396.7...
- add comment
- send to a friend
- Explore : Markets
2Vote!
Court Awards $69 Million To Health Insurers In Mylan Antitrust Suit
Covering Your Insurance Needs (Free subscription) | 01/26/2008
BOSTON (AP)–A federal court in Washington has awarded damages of $69 million to four health insurers nearly three years after a jury found that Mylan Laboratories Inc. violated antitrust laws by overcharging for two generic versions of popular Original post by Lloyd's and Elliott Back
1Vote!
Court awards $69M to health insurers in Mylan antitrust suit
Boston Globe (Free subscription) | 01/26/2008
A federal court in Washington has awarded damages of $69 million to four health insurers nearly three years after a jury found that Mylan Laboratories Inc. violated antitrust laws by overcharging for two generic versions of popular anti-anxiety drugs.
- add comment
- send to a friend
- Explore : Awards, Generic Drugs, Massachusetts
+Vote!
Biotech benchmark sets sector pace; Nektar up for second day
Market Watch (Free subscription) | 11/14/2007
BOSTON (MarketWatch) -- Biotechnology stocks rose Wednesday, outpacing their drugmaker counterparts, as shares of Nektar Therapeutics gained for a second day.
1Vote!
Drug maker Mylan Inc. reports record earnings
Today's Tribune-Review (Free subscription) | 11/01/2007
Mylan reported a 93 percent profit increase for its most recent quarter.
1Vote!
Is Forest Labs' Nebivolol Ready for Prime Time?
Fool.com (Free subscription) | 10/30/2007
A Fool's prediction on the FDA's impending decision on approval.
- add comment
- send to a friend
- Explore : Drug Manufacturers, Finance
